This is Why Institutions are Bullish on Capital One

Institutions are bullish on Capital One (SYM: COF).

Earlier this week, a firm picked up $1.45 million worth of the COF February 21, 2025 210 calls. That tells us the firm is bullish, believing the underlying COF stock could test $210 ahead of that expiration date. 

While the COF stock is a bit overbought, there are two key reasons it could push higher.

One, there is now an increased likelihood Capital One could acquire Discover Financial (DFS) this year.  The deal, which could create one of the biggest credit card issuers in the U.S. initially faced scrutiny under the Biden Administration. However, with President Trump now in office, expectations for a favorable regulatory environment raise the chances for that acquisition.

Two, Capital One just posted solid earnings.

Earnings beat expectations. Revenue was in line. However, net interest income did fall short of expectations. Adjusted EPS of $3.09 beat expectations of $2.80. Total net revenue of $10.2 billion matched estimates and jumped from $10 billion quarter over quarter. Net interest income of $8.1 billion did miss estimates of $8.18 billion but increased from $8.08 billion in the prior quarter, and from $9.51 billion year over year.

“Our fourth quarter results included steady top-line growth in our domestic card business, strong originations and a return to loan growth in our auto business, and stable credit results across our businesses,” CEO Richard Fairbank said, as quoted by Reuters.

Analysts are Bullish 

On Wednesday, RBC Capital analysts raised their price target on COF by $10 to $200. Barclays also upgraded Capital One to an overweight rating with a price target of $219.

According to Barclays, “We favor stocks with positive catalysts that have not been fully priced in and could drive additional upside,” Ma said. The upgrade for Capital One and Discover is due to the increased likelihood that their merger will proceed, better credit, and excess capital,” as quoted by Seeking Alpha.

Further Reading: Why this AI biotech is a screaming BUY NOW

This AI biotech is selling for under $10 a share and seems poised to soar in 2025…

ARK Investment recently bought 6.8 million shares…

Bayer just signed a deal worth as much as $1.5 billion to have them develop new drugs…

And NVIDIA has just partnered with them.

Get the name of the stock here.

deal of the month

best growth stocks

Alliance

Bundle package – lifetime subscriptions for all products

Categories

Recent posts

Tags

Connect with Us

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.